1. Singh A, Handa AC. Medication error- a case report of misadventure with methotrexate. JNMA J Nepal Med Assoc 2018; 56(211): 711-5.
2. Feinsilber D, Leoni RJ, Siripala D, Leuck J, Mears KA. Evaluation, identification, and management of acute methotrexate toxicity in high-dose methotrexate administration in hematologic malignancies. Cureus 2018; 10(1): e2040. doi: 10.7759/cureus.2040.
3. Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of highdose methotrexate. Oncologist 2016; 21(12): 1471-82. doi:10.1634/theoncologist.2015-0164.
4. Elmorsi YM, El-Haggar SM, Ibrahim OM, Mabrouk MM. Effect of ketoprofen and indomethacin on methotrexate pharmacokinetics in mice plasma and tumor tissues. Eur J Drug Metab Pharmacokinet 2013; 38(1): 27-32. doi:10.1007/s13318-012-0113-x.
5. Knoll K, Anzengruber F, Cozzio A, French LE, Murer C, Navarini AA. Mucocutaneous ulcerations and pancytopenia due to methotrexate overdose. Case Rep Dermatol 2016;8(3): 287-93. doi: 10.1159/000446692.
6. Lindsay K, Fraser AD, Layton A, Goodfield M, Gruss H, Gough A. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology (Oxford) 2009; 48(5):569-72. doi: 10.1093/rheumatology/kep023.
7. Gaies E, Jebabli N, Trabelsi S, Salouage I, Charfi R, Lakhal M, et al. Methotrexate side effects: review article. J Drug Metab Toxicol 2012; 3(4): 125. doi: 10.4172/2157-7609.1000125.
8. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006;11(6): 694-703. doi: 10.1634/theoncologist.11-6-694.
9. Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol 2009; 160(3): 622-8. doi: 10.1111/j.1365-2133.2008.08876.x.